A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

Immunological Reviews

Volumn 257, Issue 1, 2014, Pages 181-190

  Singh, Harjeet ^a   Huls, Helen ^a   Kebriaei, Partow ^b   Cooper, Laurence J N ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Adoptive immunotherapy; Gene therapy; Sleeping Beauty; T cells; Transposase CD19; Transposon

Indexed keywords

CD19 ANTIGEN; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA MODIFICATION; DNA VECTOR; ELECTROPORATION; GENE THERAPY; GENE TRANSFER; HUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE;

ADOPTIVE IMMUNOTHERAPY; GENE THERAPY; SLEEPING BEAUTY; T CELLS; TRANSPOSASE CD19; TRANSPOSON;

ANIMALS; ANTIGENS, CD19; CELL CULTURE TECHNIQUES; EPITOPES, T-LYMPHOCYTE; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC THERAPY; GENETIC VECTORS; HOMOLOGOUS RECOMBINATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84890209444     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12137     Document Type: Article

References (71)

1. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989;86:10024-10028.
2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993;90:720-724.
3. Singh H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res 2008;68:2961-2971.
4. Singh H, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011;71:3516-3527.
5. Serrano LM, et al. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Blood 2006;107:2643-2652.
6. Kelly SS, et al. Adoptive immunotherapy after umbilical cord blood (UCB) transplantation: manufacturing and analysis of CD19-specific UCB-derived T-cells from scant numbers of UCB mononuclear cells. Biol Blood Marrow Transplant 2010;16:S182-S183.
7. Hinrichs CS, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci USA 2009;106:17469-17474.
8. Singh H, et al. Naive CD19-specific T cells exhibit superior proliferation and potential for adoptive immunotherapy. Biol Blood Marrow Transplant 2012;18:S311-S311.
9. Deniger DC, et al. Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor. Mol Ther 2013;21:638-647.
10. Rischer M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol 2004;126:583-592.
11. Zhao Y, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009;183:5563-5574.
12. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009;21:215-223.
13. Wang J, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007;18:712-725.
14. Yvon E, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res 2009;15:5852-5860.
15. Singh H, et al. Third generation chimeric antigen receptors containing CD137 or CD134 signaling endodomains augment CD19-specific T-cell effector function. Blood 2009;114:1571-1572.
16. Bestor TH. Gene silencing as a threat to the success of gene therapy. J Clin Invest 2000;105:409-411.
17. Henikoff S. Conspiracy of silence among repeated transgenes. BioEssays 1998;20:532-535.
18. Selker EU. Gene silencing: repeats that count. Cell 1999;97:157-160.
19. Ivics Z, Izsvak Z, Minter A, Hackett PB. Identification of functional domains and evolution of Tc1-like transposable elements. Proc Natl Acad Sci USA 1996;93:5008-5013.
20. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-510.
21. Izsvak Z, Ivics Z. Sleeping beauty transposition: biology and applications for molecular therapy. Mol Ther 2004;9:147-156.
22. Hackett PB, Ekker SC, Largaespada DA, McIvor RS. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 2005;54:189-232.
23. VandenDriessche T, Ivics Z, Izsvak Z, Chuah MK. Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood 2009;114:1461-1468.
24. Huls MH, et al. Clinical application of sleeping beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp 2013;e50070.
25. Singh H, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using sleeping beauty system and artificial antigen presenting cells. PLoS ONE 2013;8:e64138.
26. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther 2010;18:674-683.
27. Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. BioEssays 2010;32:756-767.
28. Hackett PB Jr., et al. Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 2011;11:341-349.
29. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 2013;161:265-283.
30. Walisko O, et al. Transcriptional activities of the Sleeping Beauty transposon and shielding its genetic cargo with insulators. Mol Ther 2008;16:359-369.
31. Schreifels J, et al. Autoregulation of transposition of Sleeping Beauty transposons by ubiquitous N-terminal, dominant negative peptides. Mol Ther 2007;15:S128-S129.
32. Aronovich EL, McIvor RS, Hackett PB. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet 2011;20:R14-R20.
33. Manuri PV, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther 2010;21:427-437.
34. Kowolik CM, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006;66:10995-11004.
35. Kim DW, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 1990;91:217-223.
36. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB. Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol 2002;318:1221-1235.
37. Geurts AM, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003;8:108-117.
38. Maiti SN, et al. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 2013;36:112-123.
39. Mates L, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet 2009;41:753-761.
40. Jin Z, et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 2011;18:849-856.
41. Hackett PB. Integrating DNA vectors for gene therapy. Mol Ther 2007;15:10-12.
42. Nakazawa Y, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther 2011;19:2133-2143.
43. Bhatnagar P, et al. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol 2013;5:231-238.
44. Hurton LV, et al. IL-7 as a membrane-bound molecule for the costimulation of tumor-specific T cells. Blood 2009;114:1183-1183.
45. Hurton LV, et al. Tethered IL-15 mutein on CD19-specific T cells sustains persistence when tumor antigen is low and can treat minimal residual disease. Mol Ther 2013;21:S237-S237.
46. Peng PD, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther 2009;16:1042-1049.
47. Marh J, et al. Hyperactive self-inactivating piggyBac for transposase-enhanced pronuclear microinjection transgenesis. Proc Natl Acad Sci USA 2012;109:19184-19189.
48. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975;45:321-334.
49. Nemunaitis J, et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006;13:555-562.
50. Smith BD, et al. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010;16:338-347.
51. Maus MV, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143-148.
52. Le Bouteiller P, et al. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proc Natl Acad Sci USA 2002;99:16963-16968.
53. Hirano N, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1168-1176.
54. Papadimitriou L, Morianos I, Michailidou V, Dionyssopoulou E, Vassiliadis S, Athanassakis I. Characterization of intracellular HLA-DR, DM and DO profile in K562 and HL-60 leukemic cells. Mol Immunol 2008;45:3965-3973.
55. Numbenjapon T, et al. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells. Leukemia 2006;20:1889-1892.
56. Numbenjapon T, Serrano LM, Chang WC, Forman SJ, Jensen MC, Cooper LJ. Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8(+) T cells. Exp Hematol 2007;35:1083-1090.
57. Suhoski MM, et al. Engineering artificial antigen-presenting cells to express a diverse array of costimulatory molecules. Mol Ther 2007;15:981-988.
58. Zhang H, et al. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol 2007;179:4910-4918.
59. Zola H, MacArdle P, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991;69:411-422.
60. Nicholson IC, et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol Immunol 1997;34:1157-1165.
61. Jena B, et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS ONE 2013;8:e57838.
62. Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
63. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-733.
64. Singh H, et al. PET imaging of T cells derived from umbilical cord blood. Leukemia 2009;23:620-622.
65. Varadarajan N, et al. A high-throughput single-cell analysis of human CD8(+) T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest 2011;121:4322-4331.
66. Singh H, Liadi I, Romain G, Varadarajan N, Cooper LJN. Single-cell imaging reveals that subsets of T cells expressing a CD19-specific chimeric antigen receptor differ in effector function. Mol Ther 2013;21:S151-S151.
67. Liadi I, Roszik J, Romain G, Cooper LJ, Varadarajan N. Quantitative high-throughput single-cell cytotoxicity assay for T cells. J Vis Exp 2013;e50058.
68. Davies JK, et al. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 2010;70:3915-3924.
69. Torikai H, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012;119:5697-5705.
70. Torikai H, et al. Towards eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 2013;122:1341-1349.
71. Zhang M, et al. A new approach to simultaneously quantify both TCR alpha- and beta-chain diversity after adoptive immunotherapy. Clin Cancer Res 2012;18:4733-4742.